22 pharma firms see FII holding rise in Q2

Unichem Lab's FIIs holding in the company has gone down by 7.69% to 2.88% as compared to 3.12% as on June 30, 2015.

For the second quarter ended September 30, some pharma companies have attracted foreign investors, despite FPIs being net sellers to the tune of US $2.6 bn in Q2. So far, FIIs have increased their share holding in as many as 22 pharma companies.

In Caplin Point Laboratories Ltd, FIIs have increased their share holding by 82.94% to 3.11% in Q2 as against 1.70% at the end of first quarter of the current fiscal.

Neuland Laboratories has witnessed FII holding in the company go up by 16% to 1.74% as compared to 1.50% as on June 30, 2015.

FII holding in GlaxoSmithKline Pharma has increased by 3.27% to 2.21% as against 2.14% reported in Q1 FY16. Similarly, foreign investors have hiked their share holding in Divi’s Lab to 19.40% in second quarter from 19.07% in the first quarter of the current fiscal, reflecting a growth of 1.73%.

In addition, FIIs have increased their share holding in Apollo Hospitals Enterprises by 1.02% to 44.24% as on September 30; and they have taken their holding up in Shilpa Medicare Ltd by half a percent to 15.06% in the second quarter.

Unichem Lab has witnessed FIIs holding in the company go down by 7.69% to 2.88% as compared to 3.12% as on June 30, 2015.

Also, Sanofi India and Nectar Lifesciences have seen FII share holding fall by 8.17% and 6.21% respectively. FIIs currently hold 12.06% and 1.51% shares in Sanofi and Nectar respectively.

In Aurobindo Pharma, FIIs have reduced their share holding by 2.10% to 28.87 on qoq basis.